Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

Gastroenterology

Volumn 152, Issue 7, 2017, Pages 1679-1694.e3

  Chávez Talavera, Oscar ^a   Tailleux, Anne ^a   Lefebvre, Philippe ^a   Staels, Bart ^a  

^a UNIV LILLE   (France)

Author keywords

Bile Acids; FXR; Meta Inflammation; TGR5

Indexed keywords

APICAL SODIUM DEPENDENT BILA ACID TRANSPORTER; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR; BILE ACID; CYTOCHROME P450; CYTOCHROME P450 12ALPHA HYDROXYLASE B1; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FIBROBLAST GROWTH FACTOR 19; G PROTEIN COUPLED RECEPTOR; LIGAND; NORURSODESOXYCHOLIC ACID; PROTEIN INHIBITOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 19; TAKEDA G PROTEIN COUPLED RECEPTOR 5; TAKEDA G PROTEIN COUPLED RECEPTOR 5 AGONIST; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GLUCOSE; GPBAR1 PROTEIN, HUMAN; GPBAR1 PROTEIN, MOUSE;

ARTICLE; BILE ACID METABOLISM; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENERGY METABOLISM; ENTEROHEPATIC CIRCULATION; ENZYME INHIBITION; EXCRETION; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INTESTINE FLORA; INTESTINE TISSUE; LIPID METABOLISM; LIVER TISSUE; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ENERGY METABOLISM; GASTROINTESTINAL MICROBIOME; GLUCOSE; HUMANS; INFLAMMATION; LIPID METABOLISM; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85018624661     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.01.055     Document Type: Article

References (212)

1. 1 Lefebvre, P., Cariou, B., Lien, F., et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89 (2009), 147–191.
2. 2 Vlahcevic, Z.R., Stravitz, R.T., Heuman, D.M., et al. Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. Gastroenterology 113 (1997), 1949–1957.
3. 3 Duane, W.C., Javitt, N.B., 27-hydroxycholesterol: production rates in normal human subjects. J Lipid Res 40 (1999), 1194–1199.
4. 4 Takahashi, S., Fukami, T., Masuo, Y., et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J Lipid Res 57 (2016), 2130–2137.
5. 5 Duez, H., Veen JN van der, Duhem, C., et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 135 (2008), 689–698.
6. 6 Han, S., Han, S.S., Zhang, R., et al. Circadian control of bile acid synthesis by a KLF15-Fgf15 axis. Nat Commun, 6, 2015, 7231.
7. 7 Goodwin, B., Jones, S.A., Price, R.R., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6 (2000), 517–526.
8. 8 Inagaki, T., Choi, M., Moschetta, A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 (2005), 217–225.
9. 9 Ridlon, J.M., Harris, S.C., Bhowmik, S., et al. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7 (2016), 22–39.
10. 10 Ridlon, J.M., Kang, D.-J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47 (2006), 241–259.
11. 11 Steiner, C., Holleboom, A.G., Karuna, R., et al. Lipoprotein distribution and serum concentrations of 7α-hydroxy-4-cholesten-3-one and bile acids: effects of monogenic disturbances in high-density lipoprotein metabolism. Clin Sci 122 (2012), 385–400.
12. 12 Devlin, A.S., Fischbach, M.A., A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol 11 (2015), 685–690.
13. 13 Devkota, S., Wang, Y., Musch, M.W., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487 (2012), 104–108.
14. 14 Joyce, S.A., MacSharry, J., Casey, P.G., et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111 (2014), 7421–7426.
15. 15 Swann, J.R., Want, E.J., Geier, F.M., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A 108:Suppl 1 (2011), 4523–4530.
16. 16 Sayin, S.I., Wahlström, A., Felin, J., et al. gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17 (2013), 225–235.
17. 17 Degirolamo, C., Rainaldi, S., Bovenga, F., et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7 (2014), 12–18.
18. 18 Wahlström, A., Kovatcheva-Datchary, P., Ståhlman, M., et al. Induction of FXR signaling in germ-free mice colonized with a human microbiota. J Lipid Res 58 (2017), 412–419.
19. 19 Boursier, J., Diehl, A.M., Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog, 11, 2015, e1004559.
20. 20 Haeusler, R.A., Astiarraga, B., Camastra, S., et al. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 62 (2013), 4184–4191.
21. 21 Lake, A.D., Novak, P., Shipkova, P., et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 268 (2013), 132–140.
22. 22 Prinz, P., Hofmann, T., Ahnis, A., et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci, 9, 2015, 199.
23. 23 Mouzaki, M., Wang, A.Y., Bandsma, R., et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS One, 11, 2016, e0151829.
24. 24 Vrieze, A., Out, C., Fuentes, S., et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 60 (2014), 824–831.
25. 25 Jiang, C., Xie, C., Li, F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125 (2015), 386–402.
26. 26 Stadlbauer, V., Leber, B., Lemesch, S., et al. Lactobacillus casei Shirota supplementation does not restore gut microbiota composition and gut barrier in metabolic syndrome: a randomized pilot study. PLoS One, 10, 2015, e0141399.
27. 27 Reijnders, D., Goossens, G.H., Hermes, G.D.A., et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab 24 (2016), 63–74.
28. 28 Lackey, D.E., Olefsky, J.M., Regulation of metabolism by the innate immune system. Nat Rev Endocrinol 12 (2016), 15–28.
29. 29 Li, T., Jahan, A., Chiang, J.Y.L., Bile acids and cytokines inhibit the human cholesterol 7α-hydroxylase gene via the JNK/c-Jun pathway. Hepatology 43 (2006), 1202–1210.
30. 30 Ferslew, B.C., Xie, G., Johnston, C.K., et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60 (2015), 3318–3328.
31. 31 Aranha, M.M., Cortez-Pinto, H., Costa, A., et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 20 (2008), 519–525.
32. 32 Spinelli, V., Lalloyer, F., Baud, G., et al. Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. Int J Obes 40 (2016), 1260–1267.
33. 33 Jansen, P.L.M., Werven J van, Aarts, E., et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis Basel Switz 29 (2011), 48–51.
34. 34 Pournaras, D.J., Glicksman, C., Vincent, R.P., et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153 (2012), 3613–3619.
35. 35 Dutia, R., Embrey, M., O'Brien, C.S., et al. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes 39 (2015), 806–813.
36. 36 Simonen, M., Dali-Youcef, N., Kaminska, D., et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg 22 (2012), 1473–1480.
37. 37 Werling, M., Vincent, R.P., Cross, G.F., et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 48 (2013), 1257–1264.
38. 38 Steinert, R.E., Peterli, R., Keller, S., et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity 21 (2013), E660–E668.
39. 39 Kohli, R., Bradley, D., Setchell, K.D., et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 98 (2013), E708–E712.
40. 40 Ahmad, N.N., Pfalzer, A., Kaplan, L.M., Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes 37 (2013), 1553–1559.
41. 41 Sachdev, S., Wang, Q., Billington, C., et al. FGF 19 and bile acids increase following roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes. Obes Surg 26 (2016), 957–965.
42. 42 Dirksen, C., Jørgensen, N.B., Bojsen-Møller, K.N., et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes 37 (2013), 1452–1459.
43. 43 Gerhard, G.S., Styer, A.M., Wood, G.C., et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 36 (2013), 1859–1864.
44. 44 Haluzíková, D., Lacinová, Z., Kaválková, P., et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity 21 (2013), 1335–1342.
45. 45 Goncalves, D., Barataud, A., De Vadder, F., et al. Bile routing modification reproduces key features of gastric bypass in rat. Ann Surg 262 (2015), 1006–1015.
46. 46 Bhutta, H.Y., Rajpal, N., White, W., et al. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLoS One, 10, 2015, e0122273.
47. 47 Liou, A.P., Paziuk, M., Luevano, J.-M., et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med, 5, 2013, 178ra41.
48. 48 Ryan, K.K., Tremaroli, V., Clemmensen, C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 (2014), 183–188.
49. 49 Patti, M.-E., Houten, S.M., Bianco, A.C., et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 17 (2009), 1671–1677.
50. 50 Ding, L., Sousa, K.M., Jin, L., et al. Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology 64 (2016), 760–773.
51. 51 McGavigan, A.K., Garibay, D., Henseler, Z.M., et al. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 66 (2017), 226–234.
52. 52 Wang, H., Chen, J., Hollister, K., et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3 (1999), 543–553.
53. 53 Makishima, M., Lu, T.T., Xie, W., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 296 (2002), 1313–1316.
54. 54 Staudinger, J.L., Goodwin, B., Jones, S.A., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98 (2001), 3369–3374.
55. 55 Kawamata, Y., Fujii, R., Hosoya, M., et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 278 (2003), 9435–9440.
56. 56 Nagahashi, M., Yuza, K., Hirose, Y., et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J Lipid Res 57 (2016), 1636–1643.
57. 57 Sheikh Abdul Kadir, S.H., Miragoli, M., Abu-Hayyeh, S., et al. Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS One, 5, 2010, e9689.
58. 58 Han, S., Chiang, J.Y.L., Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab Dispos Biol Fate Chem 37 (2009), 469–478.
59. 59 Moore, L.B., Maglich, J.M., McKee, D.D., et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16 (2002), 977–986.
60. 60 Lee, J.M., Wagner, M., Xiao, R., et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 516 (2014), 112–115.
61. 61 Seok, S., Fu, T., Choi, S.-E., et al. Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 516 (2014), 108–111.
62. 62 Berrabah, W., Aumercier, P., Gheeraert, C., et al. Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology 59 (2014), 2022–2033.
63. 63 Kemper, J.K., Xiao, Z., Ponugoti, B., et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 10 (2009), 392–404.
64. 64 Lien, F., Berthier, A., Bouchaert, E., et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest 124 (2014), 1037–1051.
65. 65 Gineste, R., Sirvent, A., Paumelle, R., et al. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol 22 (2008), 2433–2447.
66. 66 Hashiguchi, T., Arakawa, S., Takahashi, S., et al. Phosphorylation of farnesoid X Receptor at serine 154 links ligand activation with degradation. Mol Endocrinol 30 (2016), 1070–1080.
67. 67 Kim, D.-H., Xiao, Z., Kwon, S., et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J 34 (2015), 184–199.
68. 68 Reimann, F., Habib, A.M., Tolhurst, G., et al. Glucose sensing in L cells: a primary cell study. Cell Metab 8 (2008), 532–539.
69. 69 Thomas, C., Gioiello, A., Noriega, L., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10 (2009), 167–177.
70. 70 Nagahashi, M., Takabe, K., Liu, R., et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology 61 (2015), 1216–1226.
71. 71 Cariou, B., Harmelen K van, Duran-Sandoval, D., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281 (2006), 11039–11049.
72. 72 Abdelkarim, M., Caron, S., Duhem, C., et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 285 (2010), 36759–36767.
73. 73 Watanabe, M., Houten, S.M., Mataki, C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006), 484–489.
74. 74 Broeders, E.P.M., Nascimento, E.B.M., Havekes, B., et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab 22 (2015), 418–426.
75. 75 Parséus, A., Sommer, N., Sommer, F., et al. Microbiota-induced obesity requires farnesoid X receptor. Gut 66 (2017), 429–443.
76. 76 Rizzo, G., Disante, M., Mencarelli, A., et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 70 (2006), 1164–1173.
77. 77 Fu, L., John, L.M., Adams, S.H., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145 (2004), 2594–2603.
78. 78 Fang, S., Suh, J.M., Reilly, S.M., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21 (2015), 159–165.
79. 79 Watanabe, M., Houten, S.M., Wang, L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113 (2004), 1408–1418.
80. 80 Bhatnagar, S., Damron, H.A., Hillgartner, F.B., Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 284 (2009), 10023–10033.
81. 81 Hirokane, H., Nakahara, M., Tachibana, S., et al. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 279 (2004), 45685–45692.
82. 82 Kast, H.R., Nguyen, C.M., Sinal, C.J., et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 15 (2001), 1720–1728.
83. 83 Claudel, T., Inoue, Y., Barbier, O., et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125 (2003), 544–555.
84. 84 Sirvent, A., Claudel, T., Martin, G., et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett 566 (2004), 173–177.
85. 85 Chennamsetty, I., Claudel, T., Kostner, K.M., et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 32 (2012), 1220–1227.
86. 86 Claudel, T., Sturm, E., Duez, H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109 (2002), 961–971.
87. 87 Zhang, Y., Yin, L., Anderson, J., et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 285 (2010), 3035–3043.
88. 88 Gautier, T., Haan W de, Grober, J., et al. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J Lipid Res 54 (2013), 2195–2205.
89. 89 Wang, Y., Jones, P.J.H., Woollett, L.A., et al. Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. Transl Res J Lab Clin Med 148 (2006), 37–45.
90. 90 Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet Lond Engl 385 (2015), 956–965.
91. 91 Nilsson, L.-M., Abrahamsson, A., Sahlin, S., et al. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun 357 (2007), 707–711.
92. 92 Xu, Y., Li, F., Zalzala, M., et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64 (2016), 1072–1085.
93. 93 Ferrell, J.M., Boehme, S., Li, F., et al. Cholesterol 7α-hydroxylase-deficient mice are protected from high-fat/high-cholesterol diet-induced metabolic disorders. J Lipid Res 57 (2016), 1144–1154.
94. 94 de Boer, J.F., Schonewille, M., Boesjes, M., et al. Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice. Gastroenterology 152 (2017), 1126–1138.e6.
95. 95 The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251 (1984), 351–364.
96. 96 Zweers, S.J.L.B., Booij, K.A.C., Komuta, M., et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 55 (2012), 575–583.
97. 97 Picard, A., Soyer, J., Berney, X., et al. A genetic screen identifies hypothalamic Fgf15 as a regulator of glucagon secretion. Cell Rep 17 (2016), 1795–1806.
98. 98 Dijk TH van, Grefhorst, A., Oosterveer, M.H., et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J Biol Chem 284 (2009), 10315–10323.
99. 99 Duran-Sandoval, D., Cariou, B., Percevault, F., et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 280 (2005), 29971–29979.
100. 100 Caron, S., Huaman Samanez, C., Dehondt, H., et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 33 (2013), 2202–2211.
101. 101 Kir, S., Beddow, S.A., Samuel, V.T., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331 (2011), 1621–1624.
102. 102 Katsuma, S., Hirasawa, A., Tsujimoto, G., Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329 (2005), 386–390.
103. 103 Brighton, C.A., Rievaj, J., Kuhre, R.E., et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology 156 (2015), 3961–3970.
104. 104 Trabelsi, M.-S., Daoudi, M., Prawitt, J., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun, 6, 2015, 7629.
105. 105 Popescu, I.R., Helleboid-Chapman, A., Lucas, A., et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett 584 (2010), 2845–2851.
106. 106 Kumar, D.P., Rajagopal, S., Mahavadi, S., et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun 427 (2012), 600–605.
107. 107 Kumar, D.P., Asgharpour, A., Mirshahi, F., et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet α cells to promote glucose homeostasis. J Biol Chem 291 (2016), 6626–6640.
108. 108 Seyer, P., Vallois, D., Poitry-Yamate, C., et al. Hepatic glucose sensing is required to preserve β cell glucose competence. J Clin Invest 123 (2013), 1662–1676.
109. 109 Smushkin, G., Sathananthan, M., Piccinini, F., et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 62 (2013), 1094–1101.
110. 110 Li, F., Jiang, C., Krausz, K.W., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun, 4, 2013, 2384.
111. 111 Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun, 6, 2015, 10166.
112. 112 McGettigan, B.M., McMahan, R.H., Luo, Y., et al. Sevelamer improves steatohepatitis, inhibits liver and intestinal farnesoid X receptor (FXR), and reverses innate immune dysregulation in a mouse model of non-alcoholic fatty liver disease. J Biol Chem 291 (2016), 23058–23067.
113. 113 Kaur, A., Patankar, J.V., Haan W de, et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes 64 (2015), 1168–1179.
114. 114 Yamagata, K., Daitoku, H., Shimamoto, Y., et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279 (2004), 23158–23165.
115. 115 Ma, K., Saha, P.K., Chan, L., et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116 (2006), 1102–1109.
116. 116 Stayrook, K.R., Bramlett, K.S., Savkur, R.S., et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146 (2005), 984–991.
117. 117 Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 574–582.e1.
118. 118 Lewis, N.D., Patnaude, L.A., Pelletier, J., et al. A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo. PLoS One, 9, 2014, e100883.
119. 119 Keitel, V., Donner, M., Winandy, S., et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372 (2008), 78–84.
120. 120 Ichikawa, R., Takayama, T., Yoneno, K., et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 136 (2012), 153–162.
121. 121 Guo, C., Xie, S., Chi, Z., et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45 (2016), 802–816.
122. 122 Wang, Y.-D., Chen, W.-D., Yu, D., et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology 54 (2011), 1421–1432.
123. 123 Pols, T.W.H., Nomura, M., Harach, T., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14 (2011), 747–757.
124. 124 Liu, H., Pathak, P., Boehme, S., et al. Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. J Lipid Res 57 (2016), 1831–1844.
125. 125 Gadaleta, R.M., Erpecum KJ van, Oldenburg, B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
126. 126 Vavassori, P., Mencarelli, A., Renga, B., et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183 (2009), 6251–6261.
127. 127 Inagaki, T., Moschetta, A., Lee, Y.-K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103 (2006), 3920–3925.
128. 128 Schiöth, H.B., Boström, A., Murphy, S.K., et al. A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease. BMC Genomics, 17, 2016, 462.
129. 129 Verbeke, L., Mannaerts, I., Schierwagen, R., et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep, 6, 2016, 33453.
130. 130 Fickert, P., Fuchsbichler, A., Moustafa, T., et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175 (2009), 2392–2405.
131. 131 Feaver, R.E., Cole, B.K., Lawson, M.J., et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight, 1, 2016, e90954.
132. 132 Pencek, R., Marmon, T., Roth, J.D., et al. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes Metab 18 (2016), 936–940.
133. 133 Camilleri, M., Gores, G.J., Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol 309 (2015), G209–G215.
134. 134 Schaap, F.G., Trauner, M., Jansen, P.L.M., Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 11 (2014), 55–67.
135. 135 Duan, H., Ning, M., Zou, Q., et al. Discovery of intestinal targeted TGR5 Agonists for the treatment of type 2 diabetes. J Med Chem 58 (2015), 3315–3328.
136. 136 Briere, D.A., Ruan, X., Cheng, C.C., et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS One, 10, 2015, e0136873.
137. 137 Alemi, F., Kwon, E., Poole, D.P., et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 123 (2013), 1513–1530.
138. 138 Ge, H., Zhang, J., Gong, Y., et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J Biol Chem 289 (2014), 30470–30480.
139. 139 Rao, A., Kosters, A., Mells, J.E., et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med, 8, 2016, 357ra122.
140. 140 Beraza, N., Ofner-Ziegenfuss, L., Ehedego, H., et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut 60 (2011), 387–396.
141. 141 Trauner, M., Halilbasic, E., Claudel, T., et al. Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis Basel Switz 33 (2015), 433–439.
142. 142 Mueller, M., Thorell, A., Claudel, T., et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 62 (2015), 1398–1404.
143. 143 Downes, M., Verdecia, M.A., Roecker, A.J., et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11 (2003), 1079–1092.
144. 1 Prinz, P., Hofmann, T., Ahnis, A., et al. Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients. Front Neurosci, 9, 2015, 199.
145. 2 Sonne, D.P., Nierop FS van, Kulik, W., et al. postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab 101 (2016), 3002–3009.
146. 3 Haeusler, R.A., Astiarraga, B., Camastra, S., et al. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 62 (2013), 4184–4191.
147. 4 Vincent, R.P., Omar, S., Ghozlan, S., et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem 50 (2013), 360–364.
148. 5 Wewalka, M., Patti, M.-E., Barbato, C., et al. Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin. J Clin Endocrinol Metab 99 (2014), 1442–1451.
149. 6 Cariou, B., Chetiveaux, M., Zaïr, Y., et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab, 8, 2011, 48.
150. 7 Ferslew, B.C., Xie, G., Johnston, C.K., et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60 (2015), 3318–3328.
151. 8 Patti, M.-E., Houten, S.M., Bianco, A.C., et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17 (2009), 1671–1677.
152. 9 Nakatani, H., Kasama, K., Oshiro, T., et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 58 (2009), 1400–1407.
153. 10 Jansen, P.L.M., Werven J van, Aarts, E., et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 29 (2011), 48–51.
154. 11 Pournaras, D.J., Glicksman, C., Vincent, R.P., et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153 (2012), 3613–3619.
155. 12 Simonen, M., Dali-Youcef, N., Kaminska, D., et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg 22 (2012), 1473–1480.
156. 13 Gerhard, G.S., Styer, A.M., Wood, G.C., et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 36 (2013), 1859–1864.
157. 14 Kohli, R., Bradley, D., Setchell, K.D., et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 98 (2013), E708–E712.
158. 15 Albaugh, V.L., Flynn, C.R., Cai, S., et al. Early increases in bile acids post roux-en-y gastric bypass are driven by insulin-sensitizing, secondary bile acids. J Clin Endocrinol Metab, 100, 2015, E1225 1233.
159. 16 Sachdev, S., Wang, Q., Billington, C., et al. FGF 19 and bile acids increase following roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes. Obes Surg 26 (2016), 957–965.
160. 17 Steinert, R.E., Peterli, R., Keller, S., et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity 21 (2013), E660–E668.
161. 18 Werling, M., Vincent, R.P., Cross, G.F., et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol 48 (2013), 1257–1264.
162. 19 Dutia, R., Embrey, M., O'Brien, C.S., et al. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes 39 (2015), 806–813.
163. 20 Jørgensen, N.B., Dirksen, C., Bojsen-Møller, K.N., et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 100 (2015), E396–E406.
164. 21 Ahmad, N.N., Pfalzer, A., Kaplan, L.M., Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes 37 (2013), 1553–1559.
165. 22 Dirksen, C., Jørgensen, N.B., Bojsen-Møller, K.N., et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes 37 (2013), 1452–1459.
166. 23 Haluzíková, D., Lacinová, Z., Kaválková, P., et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) 21 (2013), 1335–1342.
167. 24 Ferrannini, E., Camastra, S., Astiarraga, B., et al. Increased bile acid synthesis and deconjugation after biliopancreatic diversion. Diabetes 64 (2015), 3377–3385.
168. 1 Lefebvre, P., Cariou, B., Lien, F., et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89 (2009), 147–191.
169. 2 Pircher, P.C., Kitto, J.L., Petrowski, M.L., et al. Farnesoid X receptor regulates bile acid-amino acid conjugation. J Biol Chem 278 (2003), 27703–27711.
170. 3 Ananthanarayanan, M., Balasubramanian, N., Makishima, M., et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276 (2001), 28857–28865.
171. 4 Boyer, J.L., Trauner, M., Mennone, A., et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 290 (2006), G1124–G1130.
172. 5 Kir, S., Beddow, S.A., Samuel, V.T., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331 (2011), 1621–1624.
173. 6 Caron, S., Huaman Samanez, C., Dehondt, H., et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 33 (2013), 2202–2211.
174. 7 Zhang, L., Wang, Y.-D., Chen, W.-D., et al. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology 56 (2012), 2336–2343.
175. 8 Verbeke, L., Mannaerts, I., Schierwagen, R., et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep, 6, 2016, 33453.
176. 9 Fickert, P., Fuchsbichler, A., Moustafa, T., et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175 (2009), 2392–2405.
177. 10 Kumar, D.P., Asgharpour, A., Mirshahi, F., et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet α cells to promote glucose homeostasis. J Biol Chem 291 (2016), 6626–6640.
178. 11 Popescu, I.R., Helleboid-Chapman, A., Lucas, A., et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett 584 (2010), 2845–2851.
179. 12 Renga, B., Mencarelli, A., Vavassori, P., et al. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta 1802 (2010), 363–372.
180. 13 Kumar, D.P., Rajagopal, S., Mahavadi, S., et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun 427 (2012), 600–605.
181. 14 Inagaki, T., Choi, M., Moschetta, A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2 (2005), 217–225.
182. 15 Neimark, E., Chen, F., Li, X., et al. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatol 40 (2004), 149–156.
183. 16 Dijk TH van, Grefhorst, A., Oosterveer, M.H., et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J Biol Chem 284 (2009), 10315–10323.
184. 17 Gadaleta, R.M., Erpecum KJ van, Oldenburg, B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
185. 18 Inagaki, T., Moschetta, A., Lee, Y.-K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103 (2006), 3920–3925.
186. 19 Trabelsi, M.-S., Daoudi, M., Prawitt, J., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun, 6, 2015, 7629.
187. 20 Katsuma, S., Hirasawa, A., Tsujimoto, G., Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329 (2005), 386–390.
188. 21 Watanabe, M., Houten, S.M., Mataki, C., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006), 484–489.
189. 22 Abdelkarim, M., Caron, S., Duhem, C., et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 285 (2010), 36759–36767.
190. 23 Pols, T.W.H., Nomura, M., Harach, T., et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14 (2011), 747–757.
191. 24 Guo, C., Xie, S., Chi, Z., et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45 (2016), 802–816.
192. 25 Keitel, V., Donner, M., Winandy, S., et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372 (2008), 78–84.
193. 26 Ichikawa, R., Takayama, T., Yoneno, K., et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology 136 (2012), 153–162.
194. 1 Zhou, M., Learned, R.M., Rossi, S.J., et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63 (2016), 914–929.
195. 2 Fang, S., Suh, J.M., Reilly, S.M., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21 (2015), 159–165.
196. 3 Gadaleta, R.M., Erpecum KJ van, Oldenburg, B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60 (2011), 463–472.
197. 4 Inagaki, T., Moschetta, A., Lee, Y.-K., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103 (2006), 3920–3925.
198. 5 Dijk TH van, Grefhorst, A., Oosterveer, M.H., et al. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J Biol Chem 284 (2009), 10315–10323.
199. 6 Trabelsi, M.-S., Daoudi, M., Prawitt, J., et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun, 6, 2015, 7629.
200. 7 Jiang, C., Xie, C., Li, F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125 (2015), 386–402.
201. 8 Jiang, C., Xie, C., Lv, Y., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun, 6, 2015, 10166.
202. 9 Li, F., Jiang, C., Krausz, K.W., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun, 4, 2013, 2384.
203. 10 Zhang, L., Xie, C., Nichols, R.G., et al. Farnesoid X receptor signaling shapes the gut microbiota and controls hepatic lipid metabolism. mSystems, 1, 2016.
204. 11 Lefebvre, P., Cariou, B., Lien, F., et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89 (2009), 147–191.
205. 12 Lian, F., Wang, Y., Xiao, Y., et al. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis. Mol Med Rep 12 (2015), 5821–5827.
206. 13 Meng, Z., Wang, Y., Wang, L., et al. FXR regulates liver repair after CCl4-induced toxic injury. Mol Endocrinol 24 (2010), 886–897.
207. 14 Lee, C.G., Kim, Y.W., Kim, E.H., et al. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology 142 (2012), 1206–1217.e7.
208. 15 Verbeke, L., Mannaerts, I., Schierwagen, R., et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep, 6, 2016, 33453.
209. 16 Fickert, P., Fuchsbichler, A., Moustafa, T., et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175 (2009), 2392–2405.
210. 17 Caron, S., Huaman Samanez, C., Dehondt, H., et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 33 (2013), 2202–2211.
211. 18 Watanabe, M., Houten, S.M., Wang, L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113 (2004), 1408–1418.
212. 19 Xiong, X., Wang, X., Lu, Y., et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 60 (2014), 847–854.